File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Acute adverse reactions to magnetic resonance contrast media - Gadolinium chelates
  • Basic View
  • Metadata View
  • XML View
TitleAcute adverse reactions to magnetic resonance contrast media - Gadolinium chelates
 
AuthorsLi, A2
Wong, CS1
Wong, MK1
Lee, CM1
Au Yeung, MC1
 
Issue Date2006
 
PublisherBritish Institute of Radiology - BJR. The Journal's web site is located at http://bjr.birjournals.org
 
CitationBritish Journal Of Radiology, 2006, v. 79 n. 941, p. 368-371 [How to Cite?]
DOI: http://dx.doi.org/10.1259/bjr/88469693
 
AbstractThe objective of this study was to evaluate the clinical safety of intravenous gadolinium-based contrast media used in patients who underwent MRI at a single institution. Acute adverse reactions to intravenous gadolinium-based contrast media used for MRI at the Princess Margaret Hospital, Hong Kong, SAR, from January 1999 to November 2004 were recorded in an incidence log book. The medical records of patients' demographics were retrospectively reviewed and the nature, frequency and severity of the adverse reactions were investigated and documented. The incidence of acute adverse reactions to intravenous gadolinium-based contrast media was 0.48% (45 patients with 46 adverse reactions). The severity of these adverse reactions were 96% mild, 2% moderate (one patient developed shortness of breath that required oxygen supplementation and intravenous steroidal management) and 2% severe (one patient developed an anaphylactoid reaction, but successfully recovered through timely resuscitation). No patients were recorded as having contrast extravasation and none died as a result of any adverse reaction. Among the 45 patients who developed adverse reactions, three patients (6.7%) had prior adverse reactions to iodinated contrast media, three (6.7%) had prior reactions to a different gadolinium-based contrast agent, one (2%) had asthma and nine (20%) had a history of drug/ food allergy. Overall, 41% of the adverse reactions were not documented in the final MRI report or the clinical medical records. Gadolinium-based contrast media are safe and well tolerated by the vast majority of patients. In our study, the adverse reaction rate (0.48%) and the incidence of severe anaphylactoid reaction (0.01%) concur with those reported in the literature. Although most of the symptoms are mild and transient, these adverse reactions must be accurately documented and managed. © 2006 The British Institute of Radiology.
 
DescriptionErratum of this article, see link: http://hub.hku.hk/handle/10722/150897
 
ISSN0007-1285
2012 Impact Factor: 1.217
2012 SCImago Journal Rankings: 0.481
 
DOIhttp://dx.doi.org/10.1259/bjr/88469693
 
ISI Accession Number IDWOS:000237511700002
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorLi, A
 
dc.contributor.authorWong, CS
 
dc.contributor.authorWong, MK
 
dc.contributor.authorLee, CM
 
dc.contributor.authorAu Yeung, MC
 
dc.date.accessioned2011-02-10T04:00:53Z
 
dc.date.available2011-02-10T04:00:53Z
 
dc.date.issued2006
 
dc.description.abstractThe objective of this study was to evaluate the clinical safety of intravenous gadolinium-based contrast media used in patients who underwent MRI at a single institution. Acute adverse reactions to intravenous gadolinium-based contrast media used for MRI at the Princess Margaret Hospital, Hong Kong, SAR, from January 1999 to November 2004 were recorded in an incidence log book. The medical records of patients' demographics were retrospectively reviewed and the nature, frequency and severity of the adverse reactions were investigated and documented. The incidence of acute adverse reactions to intravenous gadolinium-based contrast media was 0.48% (45 patients with 46 adverse reactions). The severity of these adverse reactions were 96% mild, 2% moderate (one patient developed shortness of breath that required oxygen supplementation and intravenous steroidal management) and 2% severe (one patient developed an anaphylactoid reaction, but successfully recovered through timely resuscitation). No patients were recorded as having contrast extravasation and none died as a result of any adverse reaction. Among the 45 patients who developed adverse reactions, three patients (6.7%) had prior adverse reactions to iodinated contrast media, three (6.7%) had prior reactions to a different gadolinium-based contrast agent, one (2%) had asthma and nine (20%) had a history of drug/ food allergy. Overall, 41% of the adverse reactions were not documented in the final MRI report or the clinical medical records. Gadolinium-based contrast media are safe and well tolerated by the vast majority of patients. In our study, the adverse reaction rate (0.48%) and the incidence of severe anaphylactoid reaction (0.01%) concur with those reported in the literature. Although most of the symptoms are mild and transient, these adverse reactions must be accurately documented and managed. © 2006 The British Institute of Radiology.
 
dc.description.naturelink_to_OA_fulltext
 
dc.descriptionErratum of this article, see link: http://hub.hku.hk/handle/10722/150897
 
dc.identifier.citationBritish Journal Of Radiology, 2006, v. 79 n. 941, p. 368-371 [How to Cite?]
DOI: http://dx.doi.org/10.1259/bjr/88469693
 
dc.identifier.citeulike588967
 
dc.identifier.doihttp://dx.doi.org/10.1259/bjr/88469693
 
dc.identifier.epage371
 
dc.identifier.hkuros174770
 
dc.identifier.isiWOS:000237511700002
 
dc.identifier.issn0007-1285
2012 Impact Factor: 1.217
2012 SCImago Journal Rankings: 0.481
 
dc.identifier.issue941
 
dc.identifier.openurl
 
dc.identifier.pmid16632615
 
dc.identifier.scopuseid_2-s2.0-33646412592
 
dc.identifier.spage368
 
dc.identifier.urihttp://hdl.handle.net/10722/131760
 
dc.identifier.volume79
 
dc.languageeng
 
dc.publisherBritish Institute of Radiology - BJR. The Journal's web site is located at http://bjr.birjournals.org
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofBritish Journal of Radiology
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAcute Disease
 
dc.subject.meshContrast Media - adverse effects
 
dc.subject.meshDrug Hypersensitivity - etiology
 
dc.subject.meshGadolinium DTPA - adverse effects
 
dc.subject.meshMagnetic Resonance Imaging
 
dc.titleAcute adverse reactions to magnetic resonance contrast media - Gadolinium chelates
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Li, A</contributor.author>
<contributor.author>Wong, CS</contributor.author>
<contributor.author>Wong, MK</contributor.author>
<contributor.author>Lee, CM</contributor.author>
<contributor.author>Au Yeung, MC</contributor.author>
<date.accessioned>2011-02-10T04:00:53Z</date.accessioned>
<date.available>2011-02-10T04:00:53Z</date.available>
<date.issued>2006</date.issued>
<identifier.citation>British Journal Of Radiology, 2006, v. 79 n. 941, p. 368-371</identifier.citation>
<identifier.issn>0007-1285</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/131760</identifier.uri>
<description>Erratum of this article, see link: http://hub.hku.hk/handle/10722/150897</description>
<description.abstract>The objective of this study was to evaluate the clinical safety of intravenous gadolinium-based contrast media used in patients who underwent MRI at a single institution. Acute adverse reactions to intravenous gadolinium-based contrast media used for MRI at the Princess Margaret Hospital, Hong Kong, SAR, from January 1999 to November 2004 were recorded in an incidence log book. The medical records of patients&apos; demographics were retrospectively reviewed and the nature, frequency and severity of the adverse reactions were investigated and documented. The incidence of acute adverse reactions to intravenous gadolinium-based contrast media was 0.48% (45 patients with 46 adverse reactions). The severity of these adverse reactions were 96% mild, 2% moderate (one patient developed shortness of breath that required oxygen supplementation and intravenous steroidal management) and 2% severe (one patient developed an anaphylactoid reaction, but successfully recovered through timely resuscitation). No patients were recorded as having contrast extravasation and none died as a result of any adverse reaction. Among the 45 patients who developed adverse reactions, three patients (6.7%) had prior adverse reactions to iodinated contrast media, three (6.7%) had prior reactions to a different gadolinium-based contrast agent, one (2%) had asthma and nine (20%) had a history of drug/ food allergy. Overall, 41% of the adverse reactions were not documented in the final MRI report or the clinical medical records. Gadolinium-based contrast media are safe and well tolerated by the vast majority of patients. In our study, the adverse reaction rate (0.48%) and the incidence of severe anaphylactoid reaction (0.01%) concur with those reported in the literature. Although most of the symptoms are mild and transient, these adverse reactions must be accurately documented and managed. &#169; 2006 The British Institute of Radiology.</description.abstract>
<language>eng</language>
<publisher>British Institute of Radiology - BJR. The Journal&apos;s web site is located at http://bjr.birjournals.org</publisher>
<relation.ispartof>British Journal of Radiology</relation.ispartof>
<subject.mesh>Acute Disease</subject.mesh>
<subject.mesh>Contrast Media - adverse effects</subject.mesh>
<subject.mesh>Drug Hypersensitivity - etiology</subject.mesh>
<subject.mesh>Gadolinium DTPA - adverse effects</subject.mesh>
<subject.mesh>Magnetic Resonance Imaging</subject.mesh>
<title>Acute adverse reactions to magnetic resonance contrast media - Gadolinium chelates</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=0007-1285&amp;volume=79&amp;issue=941&amp;spage=368&amp;epage=371&amp;date=2006&amp;atitle=Acute+adverse+reactions+to+magnetic+resonance+contrast+media-gadolinium+chelates</identifier.openurl>
<description.nature>link_to_OA_fulltext</description.nature>
<identifier.doi>10.1259/bjr/88469693</identifier.doi>
<identifier.pmid>16632615</identifier.pmid>
<identifier.scopus>eid_2-s2.0-33646412592</identifier.scopus>
<identifier.hkuros>174770</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-33646412592&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>79</identifier.volume>
<identifier.issue>941</identifier.issue>
<identifier.spage>368</identifier.spage>
<identifier.epage>371</identifier.epage>
<identifier.isi>WOS:000237511700002</identifier.isi>
<publisher.place>United Kingdom</publisher.place>
<identifier.citeulike>588967</identifier.citeulike>
<bitstream.url>http://hub.hku.hk/bitstream/10722/131760/2/redirect.htm</bitstream.url>
</item>
Author Affiliations
  1. Princess Margaret Hospital Hong Kong
  2. United Christian Hospital Hong Kong